Europlasma, SA announced audited consolidated earnings results for the year ended December 31, 2011. For the period, the company reported revenues of EUR 58,030,000 compared to EUR 40,836,000 a year ago. Operating loss was EUR 446,000 compared to operating income of EUR 410,000 a year ago. Loss before tax from continuing operations was EUR 790,000 compared to profit before tax from continuing operations of EUR 98,000 a year ago. Loss for the year from continuing operations was EUR 624,000 compared to profit for the year from continuing operations of EUR 595,000 a year ago. Loss for the year attributable to owners of the parent was EUR 1,341,000 or EUR 0.068 per diluted share compared to profit for the year attributable to owners of the parent of EUR 628,000 or EUR 0.037 per diluted share a year ago. Net cash flows from operating activities was EUR 11,719,000 compared to net cash flows used in operating activities of EUR 284,000 a year ago. Capital expenditure on tangible and intangible assets was EUR 6,968,000 compared to EUR 5,662,000 a year ago. EBITDA was EUR 2,688,000 compared to LBITDA of EUR 864,000 a year ago. Net debt as on December 31, 2011 was EUR 3,534,000 compared to EUR 248,000 as at December 31, 2010. In contrast with the 2010 financial year, the operational performances of the Group during the 2011 financial year have been affected by non-recurring negative factors. The 2012 consolidated turnover is not expected to grow because of the CHO Morcenx plant start-up date which represents the trigger for new order taking.